NESS ZIONA, Israel, March 30, 2017 /PRNewswire/ --
Progressed to commercial stage with the signing ofVergenix™FG and Vergenix™STR distribution and sales agreements in Europe
Progressed development of
Pursuing joint ventures with international companies to further advance bioInk in specific indications in 2017
CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today provided a commercial and operational update in its annual reports.
Most recently, in November 2016, the Company announced the signing of an exclusive distribution agreement with Arthrex GMBH to distribute Vergenix™STR, CollPlant's CE Mark-approved treatment for tendinopathy, in Europe, and has supplied Arthrex with first orders. Arthrex, an affiliate of Arthrex Inc., based in Naples, FL, is a leading orthopedics company and is widely considered to be the world leader in sports medicine. Additionally, since mid-2016, CollPlant signed a number of marketing agreements for Vergenix™FG, its wound care product, covering Italy, Switzerland and Turkey. Commercial treatments have been completed over several months in Switzerland and Italy, and physicians' feedback regarding patient results have been very positive.
CollPlant has also reported extensively for the first time on the development of its collagen-based biological ink, bioInk, for use in 3D printing of organs and tissues. Specifically, the Company is developing rhCollagen-based bioInk formulations for indications including skin, orthopedics, ophthalmology, heart and lung. The Company's goal for the coming year includes working with a strategic international partner to further develop a specific indication of this product.
CollPlant's Highlights for 2016 and the start of 2017
CollPlant is a regenerative medicine company leveraging its proprietary, plant-based recombinant human collagen (rhCollagen) technology for the development and commercialization of tissue repair products, initially for the orthobiologics and advanced wound care markets. The Company's cutting-edge technology is designed to generate and process proprietary rhCollagen, among other patent-protected recombinant proteins. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix™STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; and Vergenix™FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds. CollPlant's business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.
For more information about CollPlant, visit http://www.collplant.com
Contact at CollPlant: Eran Rotem Chief Financial Officer Tel: +972-73-2325600/612 Email: [email protected]
Contact at Rx Communications Group, LLC Paula Schwartz (for US Investors) Senior Vice President Tel: +1-917-322-2216 Email: p[email protected]
Subscribe to our Free Newsletters!
Proper understanding of waste collection, segregation and management is required to reduce the ...
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...
Health insurance has emerged one of the fastest growing segments in the non-life insurance industry ...View All